MX394417B - Metodos para la administracion de ciertos inhibidores del transportador de monamina vesicular 2 (vmat2). - Google Patents
Metodos para la administracion de ciertos inhibidores del transportador de monamina vesicular 2 (vmat2).Info
- Publication number
- MX394417B MX394417B MX2019008855A MX2019008855A MX394417B MX 394417 B MX394417 B MX 394417B MX 2019008855 A MX2019008855 A MX 2019008855A MX 2019008855 A MX2019008855 A MX 2019008855A MX 394417 B MX394417 B MX 394417B
- Authority
- MX
- Mexico
- Prior art keywords
- vmat2
- methods
- vesicular
- monamin
- transporter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451605P | 2017-01-27 | 2017-01-27 | |
| PCT/US2017/055965 WO2018140095A2 (en) | 2017-01-27 | 2017-10-10 | Methods for the administration of certain vmat2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019008855A MX2019008855A (es) | 2019-09-11 |
| MX394417B true MX394417B (es) | 2025-03-24 |
Family
ID=62978647
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008868A MX393077B (es) | 2017-01-27 | 2017-10-10 | Métodos para la administración de ciertos inhibidores de proteína transportadora transportador de monoamina vesicular (vmat2). |
| MX2020003462A MX2020003462A (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| MX2019008854A MX394418B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del tranportador de monoamina vesicular 2 (vmat2). |
| MX2019008855A MX394417B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del transportador de monamina vesicular 2 (vmat2). |
| MX2019008853A MX394415B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2). |
| MX2022007141A MX2022007141A (es) | 2017-01-27 | 2019-07-25 | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular (vmat2). |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008868A MX393077B (es) | 2017-01-27 | 2017-10-10 | Métodos para la administración de ciertos inhibidores de proteína transportadora transportador de monoamina vesicular (vmat2). |
| MX2020003462A MX2020003462A (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| MX2019008854A MX394418B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores del tranportador de monoamina vesicular 2 (vmat2). |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008853A MX394415B (es) | 2017-01-27 | 2017-10-10 | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2). |
| MX2022007141A MX2022007141A (es) | 2017-01-27 | 2019-07-25 | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular (vmat2). |
Country Status (12)
| Country | Link |
|---|---|
| US (9) | US10874648B2 (enExample) |
| JP (16) | JP7199359B2 (enExample) |
| KR (14) | KR20190108147A (enExample) |
| CN (6) | CN110740732A (enExample) |
| AU (7) | AU2017395703B2 (enExample) |
| CA (5) | CA3051829A1 (enExample) |
| EA (5) | EA201991780A1 (enExample) |
| MX (6) | MX393077B (enExample) |
| MY (5) | MY202219A (enExample) |
| PH (6) | PH12022553251A1 (enExample) |
| SG (3) | SG11201906885TA (enExample) |
| WO (5) | WO2018140092A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3368534T3 (pl) | 2015-10-30 | 2021-07-12 | Neurocrine Biosciences, Inc. | Ditosylan walbenazyny i jego polimorfy |
| CN121045173A (zh) | 2015-12-23 | 2025-12-02 | 纽罗克里生物科学有限公司 | 制备3-异丁基-9,10-二甲氧基-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯的盐的方法 |
| MX393077B (es) | 2017-01-27 | 2025-03-24 | Neurocrine Biosciences Inc | Métodos para la administración de ciertos inhibidores de proteína transportadora transportador de monoamina vesicular (vmat2). |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| IL301770B2 (en) | 2017-09-21 | 2024-06-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| SG11202003194YA (en) | 2017-10-10 | 2020-05-28 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2019129100A1 (zh) | 2017-12-26 | 2019-07-04 | 苏州科睿思制药有限公司 | 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途 |
| BR112020021700A2 (pt) | 2018-04-25 | 2021-01-26 | Shinkei Therapeutics Llc | dispositivo de distribuição transdérmica de tetrabenazina |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| US20200345663A1 (en) * | 2018-06-10 | 2020-11-05 | Axsome Therapeutics, Inc. | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
| CN112867491A (zh) | 2018-08-15 | 2021-05-28 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
| CA3136466A1 (en) * | 2019-05-09 | 2020-11-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| JP2022545387A (ja) * | 2019-08-14 | 2022-10-27 | エフ．ホフマン－ラ ロシュ アーゲー | がんの処置方法 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| US20230051268A1 (en) * | 2019-12-20 | 2023-02-16 | Eisai R&D Management Co., Ltd. | Use of lemborexant for treating insomnia |
| JP2024525424A (ja) | 2021-06-30 | 2024-07-12 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 脳性麻痺によるジスキネジアの処置における使用のためのバルベナジン |
| EP4362944A1 (en) | 2021-06-30 | 2024-05-08 | Neurocrine Biosciences, Inc. | Valbenazine for use in the add-on treatment of schizophrenia |
| CA3228824A1 (en) * | 2021-08-16 | 2023-02-23 | Yuhua Li | Polymer depot compositions for sustained release delivery of vmat2 inhibitors |
| EP4387679A1 (en) | 2021-08-20 | 2024-06-26 | Neurocrine Biosciences, Inc. | Methods of screening for vmat2 inhibitors |
| EP4398893A4 (en) * | 2021-09-10 | 2025-07-16 | ATAI Life Sciences AG | IBOGAINE COMBINATION THERAPY |
| WO2023076568A1 (en) * | 2021-10-29 | 2023-05-04 | Neurocrine Biosciences, Inc. | Valbenazine compositions |
| EP4489754A1 (en) | 2022-03-07 | 2025-01-15 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| TW202430220A (zh) * | 2022-11-16 | 2024-08-01 | 逸達生物科技股份有限公司 | 用於囊泡單胺轉運蛋白2 (vmat2) 抑制劑之補給型組合物 |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025038938A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of huntington's chorea |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1068938A (en) | 1910-11-07 | 1913-07-29 | Gustav F Schulze | Vehicle-apron. |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS5283918A (en) | 1976-01-01 | 1977-07-13 | Wellcome Found | Pharmaceutical composition |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5777697A (en) | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| JPS57209225A (en) | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| JPS6028987A (ja) | 1983-07-28 | 1985-02-14 | Chugai Pharmaceut Co Ltd | 新規ジゴキシン誘導体 |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5204329A (en) | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| NZ334914A (en) | 1996-10-01 | 2000-09-29 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| CA2275422A1 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| WO2000024399A1 (en) | 1998-10-23 | 2000-05-04 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AP2001002264A0 (en) | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
| AU2003240818B2 (en) | 2002-05-28 | 2006-05-04 | Bette Pollard | Cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders |
| CA2499601A1 (en) | 2002-09-19 | 2004-04-01 | University Of Utah Research Foundation | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease |
| US7230097B2 (en) | 2003-03-10 | 2007-06-12 | Lupin Ltd. | Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid |
| GB0307259D0 (en) | 2003-03-28 | 2003-05-07 | Glaxo Group Ltd | Process |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| CN106075435A (zh) | 2004-06-04 | 2016-11-09 | 健泰科生物技术公司 | 用于治疗多发性硬化的方法 |
| CA3113166A1 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| AU2005310306A1 (en) | 2004-10-28 | 2006-06-08 | Wyeth | Coadministration of tigecycline and digoxin |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| PT1855677E (pt) | 2005-08-06 | 2009-01-13 | Cambridge Lab Ireland Ltd | 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses |
| US20100076087A1 (en) | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
| ES2402220T3 (es) | 2006-11-08 | 2013-04-29 | Neurocrine Biosciences, Inc. | Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos |
| GB0721669D0 (en) | 2007-11-02 | 2007-12-12 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| TWI423970B (zh) | 2008-01-18 | 2014-01-21 | 衛材Ｒ＆Ｄ企管股份有限公司 | 經稠合之胺基二氫噻衍生物 |
| US20110053866A1 (en) | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| GB2463452A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| GB2463451A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| CN104311552A (zh) | 2008-09-18 | 2015-01-28 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2 的苯并喹啉抑制剂 |
| US20100096319A1 (en) | 2008-10-17 | 2010-04-22 | General Electric Company | Separator assembly |
| EP2417267B1 (en) * | 2009-04-06 | 2016-08-17 | Vanda Pharmaceuticals Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
| CA2771539A1 (en) | 2009-08-12 | 2011-02-17 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenzine |
| EP3351247A1 (en) | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012153341A1 (en) | 2011-05-12 | 2012-11-15 | Arch Pharmalabs Limited | A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof |
| CA2883641C (en) | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| ES2805376T3 (es) | 2012-12-18 | 2021-02-11 | Vanda Pharmaceuticals Inc | Tasimelteón para el tratamiento de trastornos del ritmo circadiano |
| EP2951178A4 (en) * | 2013-01-31 | 2016-07-06 | Auspex Pharmaceuticals Inc | VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE |
| WO2015077521A1 (en) | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3398602A1 (en) * | 2014-01-27 | 2018-11-07 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3102190A4 (en) | 2014-02-07 | 2017-09-06 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| RU2757221C2 (ru) | 2014-02-07 | 2021-10-12 | Ньюрокрайн Байосайенсиз, Инк. | Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение |
| PT3936130T (pt) | 2014-05-06 | 2024-04-17 | Neurocrine Biosciences Inc | Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos |
| CN107438606B (zh) | 2015-02-06 | 2020-09-18 | 纽罗克里生物科学有限公司 | [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法 |
| EP4140483A1 (en) | 2015-03-06 | 2023-03-01 | Auspex Pharmaceuticals, Inc. | Methods for the treatment of abnormal involuntary movement disorders |
| MX390795B (es) | 2015-06-23 | 2025-03-21 | Neurocrine Biosciences Inc | Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos. |
| PL3368534T3 (pl) | 2015-10-30 | 2021-07-12 | Neurocrine Biosciences, Inc. | Ditosylan walbenazyny i jego polimorfy |
| CN121045173A (zh) | 2015-12-23 | 2025-12-02 | 纽罗克里生物科学有限公司 | 制备3-异丁基-9,10-二甲氧基-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯的盐的方法 |
| TW202515564A (zh) | 2016-12-02 | 2025-04-16 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| MX393077B (es) | 2017-01-27 | 2025-03-24 | Neurocrine Biosciences Inc | Métodos para la administración de ciertos inhibidores de proteína transportadora transportador de monoamina vesicular (vmat2). |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| EP3606530A2 (en) | 2017-04-01 | 2020-02-12 | Adeptio Pharmaceuticals Limited | Dihydrotetrabenazine for use in the treatment a movement disorder |
| CN110678181A (zh) | 2017-04-01 | 2020-01-10 | 阿德普蒂奥制药有限公司 | (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| HRP20220536T1 (hr) * | 2017-05-16 | 2022-06-10 | Bow River LLC | Liječenje pacijenta lijekom supstratom cyp3a4 koji je kontraindiciran za istodobnu primjenu s jakim inhibitorom cyp3a4 |
| US10857144B2 (en) * | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| IL301770B2 (en) | 2017-09-21 | 2024-06-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| SG11202003194YA (en) | 2017-10-10 | 2020-05-28 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| EP3713938A1 (en) | 2017-11-22 | 2020-09-30 | Assia Chemical Industries Ltd | Solid state form of valbenazine |
| BR112020024018A2 (pt) | 2018-06-14 | 2021-02-23 | Neurocrine Biosciences Inc. | compostos inibidores de vmat2, composições e métodos relacionados a eles |
| CN112867491A (zh) | 2018-08-15 | 2021-05-28 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
| CA3136466A1 (en) | 2019-05-09 | 2020-11-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
-
2017
- 2017-10-10 MX MX2019008868A patent/MX393077B/es unknown
- 2017-10-10 KR KR1020197024655A patent/KR20190108147A/ko not_active Ceased
- 2017-10-10 SG SG11201906885TA patent/SG11201906885TA/en unknown
- 2017-10-10 MY MYPI2020001816A patent/MY202219A/en unknown
- 2017-10-10 KR KR1020207012774A patent/KR20200066662A/ko not_active Ceased
- 2017-10-10 EA EA201991780A patent/EA201991780A1/ru unknown
- 2017-10-10 CN CN201780088766.1A patent/CN110740732A/zh active Pending
- 2017-10-10 WO PCT/US2017/055877 patent/WO2018140092A1/en not_active Ceased
- 2017-10-10 JP JP2019540557A patent/JP7199359B2/ja active Active
- 2017-10-10 MX MX2020003462A patent/MX2020003462A/es unknown
- 2017-10-10 KR KR1020257002857A patent/KR20250022883A/ko active Pending
- 2017-10-10 CA CA3051829A patent/CA3051829A1/en active Pending
- 2017-10-10 EA EA202090676A patent/EA202090676A1/ru unknown
- 2017-10-10 CN CN201780088736.0A patent/CN110709071A/zh active Pending
- 2017-10-10 JP JP2019540570A patent/JP7199361B2/ja active Active
- 2017-10-10 KR KR1020237007871A patent/KR20230038601A/ko not_active Ceased
- 2017-10-10 MY MYPI2019004293A patent/MY191077A/en unknown
- 2017-10-10 JP JP2019540568A patent/JP7199360B2/ja active Active
- 2017-10-10 KR KR1020197024656A patent/KR20190108148A/ko not_active Ceased
- 2017-10-10 CA CA3051830A patent/CA3051830A1/en active Pending
- 2017-10-10 KR KR1020237041798A patent/KR20230170136A/ko not_active Ceased
- 2017-10-10 CA CA3078719A patent/CA3078719A1/en active Pending
- 2017-10-10 KR KR1020257017150A patent/KR20250078629A/ko active Pending
- 2017-10-10 MY MYPI2019004292A patent/MY195934A/en unknown
- 2017-10-10 WO PCT/US2017/055907 patent/WO2018140093A1/en not_active Ceased
- 2017-10-10 KR KR1020257002855A patent/KR20250020722A/ko active Pending
- 2017-10-10 WO PCT/US2017/055931 patent/WO2018140094A1/en not_active Ceased
- 2017-10-10 MX MX2019008854A patent/MX394418B/es unknown
- 2017-10-10 CA CA3051832A patent/CA3051832C/en active Active
- 2017-10-10 EA EA201991786A patent/EA201991786A1/ru unknown
- 2017-10-10 AU AU2017395703A patent/AU2017395703B2/en active Active
- 2017-10-10 JP JP2020520311A patent/JP7090151B2/ja active Active
- 2017-10-10 SG SG11201906891RA patent/SG11201906891RA/en unknown
- 2017-10-10 KR KR1020237041797A patent/KR20230170135A/ko not_active Ceased
- 2017-10-10 WO PCT/US2017/055980 patent/WO2018140096A1/en not_active Ceased
- 2017-10-10 KR KR1020237041673A patent/KR20230169457A/ko not_active Ceased
- 2017-10-10 MY MYPI2019004294A patent/MY203491A/en unknown
- 2017-10-10 US US16/481,033 patent/US10874648B2/en active Active
- 2017-10-10 KR KR1020257002858A patent/KR20250020723A/ko active Pending
- 2017-10-10 JP JP2019540650A patent/JP7107950B2/ja active Active
- 2017-10-10 KR KR1020197024657A patent/KR20190108149A/ko not_active Ceased
- 2017-10-10 CN CN202310682815.1A patent/CN116712434A/zh active Pending
- 2017-10-10 CN CN201780097535.7A patent/CN111655034A/zh active Pending
- 2017-10-10 WO PCT/US2017/055965 patent/WO2018140095A2/en not_active Ceased
- 2017-10-10 AU AU2017395700A patent/AU2017395700B2/en active Active
- 2017-10-10 AU AU2017395704A patent/AU2017395704B8/en active Active
- 2017-10-10 AU AU2017395701A patent/AU2017395701B2/en active Active
- 2017-10-10 EA EA201991784A patent/EA201991784A1/ru unknown
- 2017-10-10 PH PH1/2022/553251A patent/PH12022553251A1/en unknown
- 2017-10-10 MX MX2019008855A patent/MX394417B/es unknown
- 2017-10-10 CN CN201780088897.XA patent/CN110769826A/zh active Pending
- 2017-10-10 KR KR1020197024654A patent/KR20190108146A/ko not_active Ceased
- 2017-10-10 SG SG11201906883SA patent/SG11201906883SA/en unknown
- 2017-10-10 KR KR1020207030652A patent/KR20200126430A/ko not_active Ceased
- 2017-10-10 CA CA3051834A patent/CA3051834C/en active Active
- 2017-10-10 CN CN201780088730.3A patent/CN110740731A/zh active Pending
- 2017-10-10 US US16/481,029 patent/US20190381016A1/en not_active Abandoned
- 2017-10-10 MY MYPI2019004296A patent/MY199695A/en unknown
- 2017-10-10 US US16/481,037 patent/US20200093808A1/en not_active Abandoned
- 2017-10-10 AU AU2017395702A patent/AU2017395702B2/en active Active
- 2017-10-10 MX MX2019008853A patent/MX394415B/es unknown
- 2017-10-10 EA EA201991782A patent/EA201991782A1/ru unknown
-
2019
- 2019-07-25 MX MX2022007141A patent/MX2022007141A/es unknown
- 2019-07-26 PH PH12019501732A patent/PH12019501732A1/en unknown
- 2019-07-26 PH PH12019501740A patent/PH12019501740A1/en unknown
- 2019-07-26 PH PH12019501744A patent/PH12019501744A1/en unknown
- 2019-07-26 PH PH12019501734A patent/PH12019501734A1/en unknown
-
2020
- 2020-04-08 PH PH12020550238A patent/PH12020550238A1/en unknown
- 2020-05-08 US US16/870,572 patent/US11040029B2/en active Active
- 2020-05-08 US US16/870,423 patent/US10952997B2/en active Active
- 2020-05-08 US US16/870,706 patent/US10857137B2/en active Active
- 2020-10-17 US US17/073,304 patent/US10912771B1/en active Active
- 2020-10-26 US US17/080,343 patent/US11439629B2/en active Active
- 2020-12-17 US US17/125,190 patent/US20210169862A1/en not_active Abandoned
-
2022
- 2022-01-24 JP JP2022008580A patent/JP2022040408A/ja not_active Withdrawn
- 2022-05-12 AU AU2022203201A patent/AU2022203201B2/en active Active
- 2022-05-17 AU AU2022203327A patent/AU2022203327A1/en not_active Abandoned
- 2022-07-14 JP JP2022113075A patent/JP2022137219A/ja not_active Withdrawn
- 2022-10-04 JP JP2022160177A patent/JP2022174343A/ja not_active Withdrawn
- 2022-10-05 JP JP2022160831A patent/JP2022174344A/ja not_active Withdrawn
- 2022-10-05 JP JP2022160833A patent/JP2022174345A/ja not_active Withdrawn
-
2023
- 2023-09-15 JP JP2023149999A patent/JP2023161033A/ja active Pending
-
2024
- 2024-06-06 JP JP2024092148A patent/JP2024107167A/ja active Pending
- 2024-06-06 JP JP2024092152A patent/JP2024107168A/ja active Pending
- 2024-06-06 JP JP2024092155A patent/JP2024107169A/ja active Pending
- 2024-06-07 JP JP2024093040A patent/JP2024113134A/ja active Pending
-
2025
- 2025-07-29 JP JP2025126262A patent/JP2025146959A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394417B (es) | Metodos para la administracion de ciertos inhibidores del transportador de monamina vesicular 2 (vmat2). | |
| PH12020550237A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| PH12021550302A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| MX2020013116A (es) | Sales y cristales novedosos. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CL2022000725A1 (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| CO2022015428A2 (es) | Compuesto de oxofenilarsina deuterada y uso del mismo | |
| EA202190252A1 (ru) | Способы введения определенных ингибиторов vmat2 | |
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| AR128051A1 (es) | Inhibidores de parp1 | |
| AR104427A1 (es) | Composiciones farmacéuticas para terapia de combinación |